Optimizing Treatment for Patients With Relapsed/Refractory Multiple Myeloma in the Era of Bispecific Antibodies

home / around-the-practice / optimizing-treatment-for-patients-with-relapsed-refractory-multiple-myeloma-in-the-era-of

A panel of medical oncologists offer comprehensive insights on the treatment landscape for relapsed/refractory multiple myeloma and the role of bispecific antibody therapy.

A panel of 4 experts on multiple myeloma seated at a long table

EP. 1: Recent Data in the Management of Early-Relapse Multiple Myeloma

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
October 31st 2023

A panel of oncologists give an overview of clinical trial data surrounding the management of early-relapse multiple myeloma.

A panel of 4 experts on multiple myeloma seated at a long table

EP. 2: Treatment Decision-Making in Early-Relapse MM

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
October 31st 2023

Expert perspectives on treatment decision-making in early-relapse multiple myeloma and the efficacy of CAR T-cell therapy.

A panel of 4 experts on multiple myeloma seated at a long table

EP. 3: Multiple Myeloma Treatment: Patient Profiles

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
November 7th 2023

The panel reviews the profiles of 2 patients with multiple myeloma and provides their initial thoughts regarding treatment approaches.

A panel of 4 experts on multiple myeloma seated at a long table

EP. 4: Recent Data on Bispecific Antibodies in Multiple Myeloma

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
November 7th 2023

A review of clinical trial data on bispecific antibodies in multiple myeloma and clinical insights on how these medications have changed clinical practice.

A panel of 4 experts on multiple myeloma seated at a long table

EP. 5: Dosing Considerations for Bispecific Antibodies in MM

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
November 14th 2023

Expert oncologists discuss dosing considerations for bispecific antibodies in the treatment of patients with multiple myeloma.

A panel of 4 experts on multiple myeloma seated at a long table

EP. 6: Managing Adverse Effects from Bispecific Antibodies in Multiple Myeloma

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
November 14th 2023

Comprehensive insights on the management of adverse effects from bispecific antibodies in the treatment of multiple myeloma.

A panel of 4 experts on multiple myeloma seated at a long table

EP. 7: MM: Managing Toxicities From BCMA-Targeting Bispecific Antibodies

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
November 21st 2023

Multiple myeloma specialists discuss the management of toxicities from BCMA-targeting bispecific antibodies.

A panel of 4 experts on multiple myeloma seated at a long table

EP. 8: Toxicities From GPRC5D-Targeting Therapies in Multiple Myeloma

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
November 21st 2023

The panel continues their discussion on adverse effect management with a focus on GPRC5D-targeting bispecific antibodies in multiple myeloma.

A panel of 4 experts on multiple myeloma seated at a long table

EP. 9: Treatment Decision-Making in Multiple Myeloma

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
November 28th 2023

Multiple myeloma–treating oncologists provide comprehensive insights on deciding between bispecific antibody monotherapy, combination therapy, and CAR T-cell therapy.

A panel of 4 experts on multiple myeloma seated at a long table

EP. 10: Key Takeaways on the Treatment of Patients With Relapsed/Refractory MM

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
November 28th 2023

The expert panel closes the discussion with key takeaways on the relapsed/refractory multiple myeloma treatment landscape.

A panel of experts spoke about the armamentarium of bispecific antibody therapies for patients with relapsed/refractory multiple myeloma and discussed step-up dosing considerations for these approved agents.

EP. 11: Bispecific Antibody Dose Schedules in Relapsed/Refractory Multiple Myeloma

Russ Conroy
December 26th 2023

A panel of experts spoke about the armamentarium of bispecific antibody therapies for patients with relapsed/refractory multiple myeloma and discussed step-up dosing considerations for these approved agents.